A DNA vaccine is a small, circular DNA plasmid that encode one or more protein antigens under the control of a promoter to produce immune response against disease. DNA vaccines are basically the third generation vaccines that are specifically designed to overcome the unsought properties of conventional vaccines. The increasing vulnerability of population to infectious diseases and increasing number of antibiotics resistant pathogens have created the need for effective and low-cost vaccination, which would provide long lasting immunity. DNA vaccines have potential advantages over traditional methods, e.g., low risk of infection, easy transportation and stability at room temperature. The global DNA vaccines market is experiencing rapid growth owing to the factors such as the property of specific antigen targeting, reduced risk of infection compared to conventional vaccines and improved stability. Moreover, relative ease of large-scale manufacturing compared to traditional approach and less storage requirement are some of the key market drivers.
According to World Health Organization, ~18 million people die due to the unavailability of effective treatment for infectious disease, which demonstrate global burden of infectious disease. Thus, the increasing burden of these diseases reveals the opportunity for DNA vaccines manufacturers. Moreover, rapid development in the field of molecular biology, immunology and DNA synthesis would further drive the growth of this market. Other factors such as inefficient drug therapies and increased microbial resistance to existing ‘antimicrobials and antibiotics’ treatments would likely to create the demand for DNA vaccines in near future.
The global DNA vaccines market is segmented based on type, technology, application, end user and geography. Based on type, the market is further segmented into human DNA vaccines and animal DNA vaccines. Based on technology, the DNA vaccines market is further segmented into DNA vaccine technology and DNA delivery technology. Based on applications, the market is further segmented into human disease i.e., oncology, infectious disease, allergies and others; and veterinary diseases i.e. Canine Melanoma, Leishmaniasis, Equine West Nile Virus, and others. Based on end user, the market is segmented into human health, animal health and research application. Based on geography, the market is segmented into North America, Europe, Asia-Pacific and LAMEA. Companies profiled in the report includes Sanofi Aventis, Pfizer Pharmaceuticals, Novartis AG, Merck & Co., GlaxoSmithKline Inc., Advance Bioscience Laboratories Inc., Indian Immunologicals Ltd., Xenetic Biosciences Inc., QED Biosciences Inc..
KEY MARKET BENEFITS
KEY MARKET SEGMENTS
The global DNA vaccines market is segmented as below:
Global DNA vaccines market - By Types
Global DNA vaccines market - By Technology
Global DNA vaccines market- By Application
Global DNA vaccines market- by End User
Global DNA vaccines market- By Geography